Clinical Trials Browser

Breast Neoplasms × volagidemab × Breast × Clear all

NCT04330625 2022-11-08

Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)

Phase 1 Terminated

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies